Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.84 CAD | -1.40% | -7.87% | +45.56% |
Jun. 06 | Acreage Closes US$10-Million Private Placement of Convertible-Debenture Units | MT |
Jun. 06 | Toronto Stocks Edge Higher; Transcontinental Rises on Higher 2Q Adjusted Profit | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an enterprise value anticipated at 3.93 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+47.63% | 553M | C- | ||
+41.50% | 6.2B | B- | ||
-22.89% | 4.1B | C+ | ||
+9.36% | 3.41B | C | ||
-19.39% | 2.83B | B- | ||
-11.05% | 2.29B | - | D+ | |
+45.24% | 1.93B | - | ||
-7.51% | 1.52B | - | - | |
+46.81% | 1.51B | - | ||
-18.04% | 1.49B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WEED Stock
- Ratings Canopy Growth Corporation